New hope for sickle cell patients facing kidney failure
NCT ID NCT06286046
Summary
This study is testing whether an oral drug called mitapivat can help protect the kidneys of people with sickle cell disease. It will enroll about 40 participants who already show signs of early kidney damage. Researchers will measure protein levels in urine over 6 months to see if the drug reduces kidney stress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.